Monthly Maintenance Items for FormsNet3

Each month the FormsNet3 team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.

July 2024 (released July 26th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r9	Q4 & 5-11	Validation (Modify)	Q4 is disabled and Q5-11 are enabled	Q4 is enabled, Q5-11 are disabled	Align with changes to infusion reporting workflow.
F2100 r9	Q3 & 4-9	Validation (Modify)	Q3 is disabled and Q4-9 are enabled	Q3 is enabled and Q4-9 are disabled	Align with changes to infusion reporting workflow.
F2100 r9	Q275, 279, 355	Validation (Add)	No current validation for Q275. Q279 must be answered. No current validation for Q355.	If visit is greater than or equal to 2Y, then Q275 cannot be equal to VOD/SOS option. If visit is equal to 100D, 6M or 1Y, then Q279 must be answered. If visit is greater than or equal to 2Y, then Q355 cannot be equal to hemorrhagic cystitis/hematuria.	Necessary for certain organ impairments to be disabled after the 1Y reporting period.
F2100 r9		Validation (Modify)	If Q257 contains any (BR_OBLIT, COP_BOOP, DAH, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q272 = yes, then Q277 must be answered. If and only if Q319 = yes, then Q333 must be answered. If and only if Q344 = pancreatitis, then Q350 must be answered.	If Q257 contains any (BR_OBLIT, COP_BOOP, OTH_NONINF_PULM), then Q264 must be answered. If and only if Q275 = any VOD, medication toxicity, other toxicity, or unknown etiology, then Q277 must be answered. If and only if Q322 = hyperlipidemia, then Q333 must be answered. Q350 must not be answered.	Burden reduction. Some organ impairments do not require a resolution date.
F2400 r10	Q12	Validation (Modify)	If and only if Q44 = any, or infusion type = allo, then Q12 must be answered	If and only if Q44 = any, then Q12 must be answered for first allo HCT and disabled for subsequent infusions	Burden reduction.
F2400 r10	Q77	Validation (Modify)	If and only if Q44 = auto, then Q77 must be answered	Q77 is disabled for gene therapy infusions	Reduce duplicate reporting, as Q77 is now collected on F2003r2 (Gene Therapy Product Form).

June 2024 (released June 21, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2018 r6	Q83	Validation (Modify)	Q83 must be equal to F2402 Q401	Q83 must be equal to F2402 Q400	Correction to validation
F2402 r7		Validation (Modify)	If and only if Q91 is equal to any, then Q93 must be answered	If date received is not answered or is greater than 2024-01-26 and Q91 is equal to any, then Q93 must be answered If date received is less than or equal to 2024-01-26 and Q91 is equal to any, then Q93 is optional	Validations updated so that when edits are made to F2402s completed prior to January 2024 release, no errors will populate on unanswered MRD questions
			If and only if Q167 is equal to any, then Q169 must be answered	If date received is not answered or is greater than 2024-01-26 and Q167 is equal to any, then Q169 must be answered If date received is less than or equal to 2024-01-26 and Q167 is equal to any, then Q169 is optional
F2402 r8	Q217	Validation (Add)	If Q195 is equal to any, then Q217 must be answered	If Q195 is equal to any, then Q217 must be answered (additional subtypes added)	Data quality improvement

May 2024 (released May 17, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4100 r9	Q148	Validation (Modify)	If latest track for CT event = 15 year follow-up or standard follow-up CRF, then Q148 must be answered	If latest track for CT event = 15 year follow-up or standard follow-up CRF AND treatment path for current event = CT, then Q148 must be answered	Burden reduction, Q148 will only be answered if the combined follow-up event is a CT

April 2024 (released April 19, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9	Q245-249	Validation (Modify)	Covid-19 vaccine questions must be answered	Questions disabled	Burden reduction, no longer collecting data
F2400 r10	Q87-94	Validation (Modify)	Covid-19 infection and vaccine questions must be answered	Questions disabled
	Q95	Modify (Floating Text)	Is there a history of mechanical ventilation (excluding COVID-19 (SARS-CoV-2))?	Is there a history of mechanical ventilation?
F2450 r7	Q49-55	Validation (Modify)	Covid-19 infection and vaccine questions must be answered	Questions disabled
F4000 r10	Q81-90	Validation (Modify)	Covid-19 pre-exposure drugs, infection and vaccine questions must be answered	Questions disabled
F4100 r9	Q183-189	Validation (Modify)	Covid-19 pre-exposure drugs and vaccine questions must be answered	Questions disabled
F2003 r1	Q13 and 20	Validation (Modify)	Questions must be answered	If and only if Q1 = other, then Q13 and Q20 must be answered	Burden reduction
F2037 r3	Q54	Smart Navigation	If Q54 = normal, then go to Q57	If Q54 = normal, then go to Q55	Data quality improvement, gadolinium information being collected
	Q55	Validation (Modify)	If and only if Q54 = abnormal, then Q55 must be answered	If Q54 is answered, then Q55 must be answered
F2137 r3	Q37	Smart Navigation	If Q36 = normal, then go to Q39	If Q36 is answered, then go to Q37	Data quality improvement, gadolinium information being collected
		Validation (Modify)	If and only if Q36 = abnormal, then Q37 must be answered	If Q36 is answered, then Q37 must be answered
F2100 r9	Q140, 389, 390, 393, 395, 399 and 400	Validation (Modify)	Question validations based on patient’s current age	Question validations based on patient’s age at date of contact reported on follow-up form	Data quality improvement, prevent errors if correcting old data
F2110 r4	Q104	Modify (Floating Text)	No floating text	Floating text added to indicate when each answer option should be selected	Eliminate reporting confusion
		Validation (Add)		If Q51, Q63, Q70, Q80, Q87 = no, then Q104 must be no
F2111 r4	Q95	Modify (Floating Text)	No floating text	Floating text added to indicate when each answer option should be selected	Eliminate reporting confusion
		Validation (Add)		If Q48, Q54, Q61, Q71, Q78 = no, then Q95 must be no
F2114 r4	Q172	Modify (Floating Text)	No floating text	Floating text added to indicate when each answer option should be selected	Eliminate reporting confusion
		Validation (Add)		If Q88 = not answered or no or not applicable and Q94 = not answered or no and Q100, Q109, Q118, Q137, Q144, Q148 = no, then Q172 must be no
F2157 r1	Q203	Modify (Floating Text)	No floating text	Floating text added to indicate when each answer option should be selected	Eliminate reporting confusion
		Validation (Add)		If Q105 = no or not applicable and Q111, Q117, Q130, Q139, Q167, Q174, Q178 = no, then Q203 must be no

March 2024 (released March 22nd, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F4006 r6	Q33	Validation (Add)	Q33 (Specify start date) must be between date of product infusion and date of product infusion +2 days.	Q33 (Specify start date) must be greater than or equal to event date	Allows for a broader date range to be reported
F2003 r1	Q3-5	Validation (Modify)	If and only if Q2 = Gene Therapy product ID, then Q3 must be answered. If and only if Q2 = Batch number, then Q4 must be answered. If and only if Q2 = Lot number, then Q5 must be answered.	If Q2 contains Gene Therapy product ID, then Q3 must be answered. If Q2 contains Batch number, then Q4 must be answered. If Q2 contains Lot number, then Q5 must be answered.	Fixing previously incorrect validations to work as initially intended

February 2024 (released February 23rd, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r7	Q415	Validation (Modify)	If Q413 is multiple myeloma then Q415 may contain any combination of heavy and light chain options	If and only if Q413 is answered as multiple myeloma then Q415 must contain only heavy chain OR only light chain options. Will receive error if both heavy and light chain options are reported together	Prevent contradicting information from being reported
F2100 r9	Q121 and 191	Modify (Floating Text)	Brand names listed next to drug options	Brand names no longer listed next to drug options. Only generic drug names are listed on form	Eliminate reporting confusion

January 2024 (released January 26th, 2024)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r7	Q469-501	Validation (Modify)	Q469-501 are required for Thalassemia	Q469-501 will still be required for Thalassemia. Q469-474, 477-494 & 499-501 will be answered for Sickle Cell Disease	These questions will now be required for both Thalassemia and Sickle Cell Disease (previously only required for Thalassemia)
F2030 r3	Q28-29, 38-40, 41-46	Validation (Modify)	If Q27 = yes, then Q28 must be answered. Q38 & Q41 must be answered	Q28, 38 & 41 no longer need to be answered	Because these questions are now answered on F2402 (see above revision), they will be disabled on F2030 to avoid duplicate reporting
F2402 r7	Q93-101, 169-177	Validation (Modify)	MRD questions are disabled	MRD questions are enabled AML: Q93-95 & 99-101 ALL: Q169-171 & 175-177	For AML and ALL, these MRD questions are now required to be answered

December 2023 (released December 8th, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9	Q209-211	Validation (Add)	Questions required only for recipients with acute or chronic GVHD	Questions required for all ALLO recipients regardless of GVHD status	Information required for all ALLO patients
F2100 r9	Q348-349	Validation (Modify)	Active questions	Inactive questions	No longer collecting data Note: If questions were previously answered, data will be removed from form
F2116 r5	Q110-141	Validation (Add)	If Q4 = yes, must answer Q110-141	Will not need to re-answer Q110-141	Burden reduction
F2116 r5	Q228 and Q230	Validation (Modify)	Questions must always be answered	If Q1 = AMYL or MRGS OR Q2 contains AMYL or MGRS, then Q228 and 230 must be answered	Only captured at baseline for AMYL or MGRS and should only be captured for same diseases at follow-up Note: If questions were previously answered for data that is not AMYL or MGRS, data will be removed from form
F2014/2114, F2016, F2028/2128, F2057/2157		Validation (Modify)	Karyotype ISCN string field does not exist	Karyotype ISCN string field added	Expanding functionality

November 2023 (released November 17th, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r9	Q317	Validation (Modify)	If cardiac impairment/disorder = arrhythmia or pericarditis, then Q317 must be answered	If cardiac impairment/disorder = arrhythmia, pericarditis or cardiomyopathy, then Q317 must be answered	Cardiomyopathy has been added as a cardiac impairment/disorder that, when reported, makes Q317 required
F2402 r7	Q92 & Q168	Validation (Modify)	If disease status = 1CR, 2CR, or GE3CR, then number of cycles of induction therapy required to achieve 1st CR must be answered	If disease status = 1CR, then number of cycles of induction therapy required to achieve 1st CR must be answered	A disease status that is anything but 1CR implies the disease is more aggressive. Thus, only patients in 1CR should have this question answered
F2116 r5	Q30	Validation (Modify)	If Q1 = amyloidosis, MGRS or other PCD OR Q2 contains amyloidosis or MGRS, then Q30 must be answered If Q4 or Q7 = no, then Q30 must be answered	If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q30 must be answered	Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users
F2116 r5	Q32	Validation (Modify)	If Q1 = amyloidosis, MGRS, other PCD OR Q2 = amyloidosis or MGRS, then Q32 must be answered If Q4 or Q7 = no, then Q32 must be answered	If Q1 = MGRS or Q2 contains MGRS and Q4 = no OR Q1 = amyloidosis or Q2 contains amyloidosis and Q7 = no, then Q32 must be answered	​Previous validations were combined into a single validation to prevent contradicting validations and incorrect errors occurring for users
F2400 r10	Q61	Validation (Modify)	If Q45 contains single cord blood unit or Q44 = allogeneic, unrelated and Q55 is not answered, then Q61 must be answered	If Q45 contains single cord blood unit and Q53 = no OR Q44 = allogeneic, unrelated and Q45 contains any (BM, PBSC, Other) and Q55 is not answered, then Q61 must be answered	Cord blood units facilitated through NMDP are not required to answer the Cord Blood Bank, this question is now optional. Note: optional fields will appear enabled, but there will not be a validation error if it is left blank

October 2023 (released October 27, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2402 r6	Q18, 45, 72, 110, 129, 148, 213, 250, 301, 358, 436	Validation (Add)	ISCN validations do not exist	ISCN validations added	Support AGNIS centers using 2402r6

September 2023 (released September 22, 2023)

No updates to communicate.

August 2023 (released August 25, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2100 r7-8 F2149 r1 F2900 r4-5 F4100 r5-9		Events and Actions	If COVID-19 (SARS-CoV-2) infection is reported F2149 comes due	F2149 will not come due	Data no longer being collected except for BMT CTN 2101 study
F2149 r1		Events and Actions	On-demand capability enabled	On-demand capability removed, CIBMTR will add form manually	Data no longer being collected except for BMT CTN 2101 study

July 2023 (released July 28, 2023)

Form_Revision	Question	Type of Change	Current	New	Rationale for Change
F2000 r6	Q115	Validation (Modify)	If country of primary residence is EQUAL to any (AS, GU, MP, PR, US, UM, VI) then household income must be answered	Household income question will be disabled for all	To coincide with cell therapy form updates and reduce reporting burden
F4000, F4100, F4003, F4006, F4101		Option group (add and modify)		Afamitresgene autoleucel added to cell therapy product list and Orvacabtagene autoleucel removed from cell therapy product list	Changes in availability/production of cell therapy products
F2400 r10	Q19	Option group (add)		Four COG studies added to the dropdown list. These include: COG AALL1732, COG AAML1831, COG APAL2020SC (PedAL) and COG ASCT2031	Updating list to include additional studies
F2400 r10 and F4000 r10	Q17 (F2400) and Q9 (F4000)	Option group (modify)	Study sponsor list includes “RCI BMT”	“RCI BMT” has been changed to “CIBMTR CRO Services”	Change in sponsor name​
F2400 r10 and 2003 r1	Q79 (2400) and Q1 (2003)	Option group (add)	Only option for gene therapy product name is “other name”	New options for gene therapy products added. Product options include: Betibeglogene autotemcel (Zynteglo®), Elivaldogene autotemcel (Skysona®), Exagamglogene autotemcel and Other name (specify)	Updating list to add gene therapy product names

Copyright © 2004-2024 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.